37.01
                                            전일 마감가:
              $37.29
            열려 있는:
              $37.43
            하루 거래량:
                481.64K
            Relative Volume:
              0.97
            시가총액:
                $1.61B
            수익:
              $384.10M
            순이익/손실:
              $-9.07M
            주가수익비율:
              -264.36
            EPS:
                -0.14
            순현금흐름:
                $11.10M
            1주 성능:
              -4.93%
            1개월 성능:
              -4.69%
            6개월 성능:
                +37.23%
            1년 성능:
              +63.83%
            Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
                  
                      Kiniksa Pharmaceuticals International Plc
                    
                전화
                  
                      (781) 431-9100
                    
                주소
                  
                      23 OLD BOND STREET, FLOOR 3, LONDON
                    
                KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 | 
|---|---|---|---|---|---|---|
|   
                          
                                KNSA
                            
                             Kiniksa Pharmaceuticals International Plc | 37.01 | 2.76B | 384.10M | -9.07M | 11.10M | -0.14 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 | 
|---|---|---|---|
| 2025-09-29 | 개시 | TD Cowen | Buy | 
| 2025-03-13 | 개시 | Citigroup | Buy | 
| 2024-09-13 | 개시 | Jefferies | Buy | 
| 2024-05-03 | 개시 | Wells Fargo | Overweight | 
| 2020-06-29 | 재확인 | BofA Securities | Buy | 
| 2020-04-01 | 개시 | BofA/Merrill | Buy | 
| 2019-03-11 | 개시 | Barclays | Overweight | 
| 2018-12-12 | 재확인 | Wedbush | Outperform | 
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform | 
                    모두보기
                     
                  
                Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Equities Analysts Offer Predictions for KNSA FY2025 Earnings - MarketBeat
Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows - MSN
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock - Investing.com
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock By Investing.com - Investing.com UK
New Strong Sell Stocks for Oct. 30th - The Globe and Mail
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage - Seeking Alpha
Goldman Sachs Raises Target Price for Kiniksa Pharmaceuticals (K - GuruFocus
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win - Yahoo! Finance UK
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates - sharewise.com
Kiniksa Pharmaceuticals International, plc SEC 10-Q Report - TradingView
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighHere's Why - MarketBeat
Kiniksa Ramps Up Revenue Forecast As ARCALYST Gains Traction - Finimize
Key Developments in KNSA Revenue Forecasts - GuruFocus
KNSA Surpasses Revenue Expectations and Updates Sales Forecast - GuruFocus
Kiniksa Pharmaceuticals Q3 2025 Earnings: Revenue Surpasses Esti - GuruFocus
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results - TradingView
Kiniksa Pharma raises ARCALYST's 2025 sales forecast - MarketScreener
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals (NASDAQ: KNSA) raises ARCALYST net sales guidance to $670–$675M - Stock Titan
Peregrine Capital Management LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Hits New 52-Week High of $39.60 - Markets Mojo
Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KN - GuruFocus
Allspring Global Investments Holdings LLC Sells 29,796 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Michael Megna Sells 50,490 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 97,390 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 - The Manila Times
Kiniksa (Nasdaq: KNSA) sets Oct 28 8:30 a.m. ET webcast for third‑quarter results - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,524,862.87 in Stock - MarketBeat
Kiniksa Pharma CEO Patel sells $10 million in shares By Investing.com - Investing.com South Africa
Kiniksa Pharma CEO Patel sells $10 million in shares - Investing.com India
Kiniksa Pharmaceuticals (KNSA): Investor Outlook on a 29% Upside Potential in the Biopharma Space - DirectorsTalk Interviews
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High After Analyst Upgrade - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Citigroup Boosts Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $50.00 - Defense World
Cannon Global Investment Management LLC Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
FDA grants orphan drug designation to Kiniksa’s pericarditis treatment By Investing.com - Investing.com Canada
Eben Tessari Sells 12,368 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals (KNSA) Sees 11% Increase in Citigroup's Price Target | KNSA Stock News - GuruFocus
FDA grants orphan drug designation to Kiniksa’s pericarditis treatment - Investing.com
Kiniksa (KNSA) Receives FDA Orphan Drug Status for Pericarditis Treatment - GuruFocus
Kiniksa Pharmaceuticals Says Pericarditis Treatment Candidate Got US FDA Orphan Drug Designation - MarketScreener
Kiniksa Pharmaceuticals Receives Orphan Drug Designation from FDA for KPL-387 in Treating Pericarditis - Quiver Quantitative
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis - GlobeNewswire
Kiniksa Pharma COO Tessari sells $465,843 in shares By Investing.com - Investing.com Nigeria
KNSA Awarded FDA Orphan Designation for Pericarditis Treatment - GuruFocus
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - sharewise.com
Kiniksa Pharma COO Tessari sells $465,843 in shares - Investing.com India
Wedbush Issues Positive Forecast for KNSA Earnings - Defense World
Earnings call transcript: Kiniksa Pharmaceuticals sees strong Q2 2025 growth By Investing.com - Investing.com UK
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kiniksa Pharmaceuticals International Plc 주식 (KNSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 | 
|---|---|---|---|---|---|---|---|
| Ragosa Mark | CHIEF FINANCIAL OFFICER | Oct 28 '25 | Sale | 41.00 | 100 | 4,100 | 31,086 | 
                자본화:
                 
                  | 
                볼륨(24시간):
                 
            
         
                     
                             Stockscreener 앱 받기
                    Stockscreener 앱 받기